Abstract
The effects of mithramycin, an antibiotic with cytotoxic activity, were observed in 15 patients with active Paget's disease of bone. Mithramycin is shown to have a consistent effect in suppressing the activity of Paget's disease, as reflected by changes in serum alkaline phosphatase and urinary hydroxyproline levels, and the occurrence of symptomatic relief. These responses are probably mediated by a cytotoxic effect on osteoclasts. Several patients have shown prolonged remissions. This agent shows considerable promise as an effective treatment for Paget's disease of bone but means of enhancing the therapeutic:toxicity ratio need further investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
